Talk:Hepatic veno-occlusive disease
 | Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||
| ||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Hepatic veno-occlusive disease.
|
 | The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.
|
Accuracy
I edited this page a while back because the 30% fatality is not at all accurate. It is rarely fatal in mild cases and almost always fatal in severe cases. Someone came by and changed it back. Care to discuss? 76.112.199.81 (talk) 16:14, 27 April 2010 (UTC)
- Also, there is no link to the verify the 30% but I can provide 10+ links to verify mine. I will change it in a few days if there is no response.
Guideline
In HSCT-related VOD, the following guideline can be considered authoritative: doi:10.1111/bjh.12558 - mentions scoring criteria etc so probably a good source for this article in general. JFW | T@lk 22:05, 27 October 2013 (UTC)
How I manage
doi:10.1111/bjh.13215 (HSCT-related SOS, from Br J Haem). JFW | T@lk 17:45, 19 November 2014 (UTC)
Updated Information
| The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.
|
I am an employee of Jazz Pharmaceuticals, Inc (Jazz). My intent is to correct misinformation related to Jazz products or related disease states in a truthful and non-misleading manner. All of the edits that I request are made with the knowledge and approval of Jazz.
In October 2013, EMA approved Defitelio (defibrotide sodium) for the treatment of severe hepatic veno-occlusive disease (VOD) in haematopoietic stem-cell transplantation (HSCT) therapy. In March 2016, the FDA approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic VOD with renal or pulmonary dysfunction after they undergo HSCT.
I suggest making edits to the Treatment section of the Hepatic Veno-Occlusive Disease Wikipedia article in order to correct the information stating that defibrotide is an investigational treatment.
 | This edit request by an editor with a conflict of interest has now been answered. |
The following edits to the Treatment section are suggested to reflect the approval of defibrotide in Europe and the United States:
Treatment for VOD is primarily supportive. (Please delete text from “In the BMT setting, defibrotide…” through “…for this indication is uncertain” and replace with the following text.)
In October 2013, EMA approved Defitelio ([[1]]) for the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), in haematopoietic stem-cell transplantation (HSCT) therapy.” [1] The current SmPC is available on the EMA website. In March 2016, the FDA approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic VOD with renal or pulmonary dysfunction after they receive a HSCT.”[2] The current Defitelio package insert is also available online.
The following edits to the Prognosis section are also suggested based on recently available information:
(Please delete first sentence of this section, “When associated with bone marrow transplant, VOD is fatal in over 30% of cases” and replace with the following text prior to the current last sentence beginning “Cases due to…”)
The prognosis of VOD depends on the severity of the disease. In a study that evaluated incidence of VOD based on two sets of diagnostic criteria, approximately 30% to 50% of cases developed VOD with multi-organ dysfunction, a more severe form of the disease.[3] In a large meta-analysis, VOD with multi-organ dysfunction was associated with greater than 80% mortality rate.[4]
--CPark 2017 (talk) 21:45, 13 July 2017 (UTC)CPark_2017
- per MEDRS would only add #2 and #4 ref(though the text that reflects these references would need to be adjusted)...IMO--Ozzie10aaaa (talk) 16:47, 17 July 2017 (UTC)
References
- ^ "Gentium Receives Marketing Authorization From the European Commission for Defitelio (R) (Defibrotide)". October 22, 2013.
{{cite news}}: Check date values in:|date=(help) - ^ "FDA Approves First Treatment for Rare Disease in Patients Who Receive Stem Cell Transplant From Blood or Bone Marrow". March 30, 2016.
{{cite news}}: Check date values in:|date=(help) - ^ Carreras E, Díaz-Beyá M, Rosiñol L, Martínez C, Fernández-Avilés F, Rovira M (2011). "The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade". Biol Blood Marrow Transplant. 17 (11): 1713–1720. doi:10.1016/j.bbmt.2011.06.006. PMID 21708110.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Coppell JA, Richardson PG, Soiffer R; et al. (2010). "Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome". Biol Blood Marrow Transplant. 16 (2): 157*168. doi:10.1016/j.bbmt.2009.08.024. PMID 19766729.
{{cite journal}}: Explicit use of et al. in:|last1=(help)CS1 maint: multiple names: authors list (link)